Full Breakdown
Risks of Discontinuing GLP-1 Medications: A Study's Findings
3/19/2026, 8:56:04 AM
Overview of the Study's Findings
A recent study conducted by researchers at Washington University School of Medicine highlights the cardiovascular risks associated with discontinuing GLP-1 medications, such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro). Published in BMJ Medicine, the research analyzed electronic health records of over 333,000 adults with Type 2 diabetes over three years, revealing that stopping these medications can significantly increase the risk of heart attack, stroke, and death.
Key Data Points
The study found that patients who maintained continuous use of GLP-1s experienced an 18% reduction in cardiovascular risk. However, those who interrupted their treatment for as little as six months saw a 4% increase in risk, while a two-year gap resulted in a 22% increase compared to continuous users. Dr. Ziyad Al-Aly, the study's lead author, described this phenomenon as "metabolic whiplash," where the benefits of treatment quickly diminish after discontinuation.
Discontinuation Rates and Challenges
Discontinuation rates for GLP-1 medications are notably high, ranging from 36% to 81%. Factors contributing to these rates include side effects such as nausea and vomiting, as well as issues with access and affordability. Many patients stop taking these medications due to cost, particularly when prescribed for obesity, as insurance coverage for weight-loss treatments is less common than for diabetes medications.
Implications for Patient Care
The findings underscore the necessity for healthcare providers to emphasize the importance of long-term treatment with GLP-1 medications. Dr. Al-Aly noted that maintaining patients on these drugs should not be an afterthought, advocating for proactive management of side effects and addressing cost barriers. He stated, "People need to realize that there's a price of stopping."
Official Statements & Responses
Health systems are encouraged to develop strategies to support continuous GLP-1 treatment, recognizing that these medications are designed for chronic conditions. This includes identifying patients at risk of discontinuation and implementing infrastructure to assist them. The study's results indicate that the cardiovascular protection provided by GLP-1 medications builds slowly but erodes quickly, making continuous treatment essential for sustained health benefits.
Verbatim Quotes
- “It takes a whole lot of time to build protection, and half as much to undo it.” — Dr. Ziyad Al-Aly, Epidemiologist, Washington University School of Medicine
- “Our data suggest this metabolic whiplash is detrimental to heart health,” — Dr. Ziyad Al-Aly
- “Health systems need plans in place to help people continue their medication indefinitely, recognizing that GLP-1s treat chronic conditions.” — Dr. Ziyad Al-Aly
What's Next
As major pharmaceutical companies like Eli Lilly work to improve insurance coverage for obesity treatments, the landscape for GLP-1 medications may evolve. Future research may focus on developing next-generation treatments that offer similar benefits with fewer side effects, aiming to reduce the high rates of discontinuation and enhance patient outcomes.
